Literature DB >> 3311205

Variability in 4-hydroperoxycyclophosphamide activity during clinical purging for autologous bone marrow transplantation.

R J Jones1, M Zuehlsdorf, S D Rowley, J Hilton, G W Santos, L L Sensenbrenner, O M Colvin.   

Abstract

We examined the effects of varying incubation conditions on the in vitro activity of 4-hydroperoxycyclophosphamide (4HC). 4HC activity against CFU-GM and against the K562 tumor cell line decreased with increasing the RBC concentration of the incubation mixture. Increasing the concentration of nucleated bone marrow cells in the incubation mixture also decreased the 4HC activity. Evaluation of 53 consecutive patients undergoing autologous bone marrow transplantation (BMT) revealed that the incubation RBC concentration during clinical purging showed a similar effect on CFU-GM recovery. Aldehyde dehydrogenase content of RBCs and nucleated marrow cells appears to be the cause of the inhibition of 4HC activity. Although there was no difference in individual CFU-GM sensitivity to 4HC among normals, previously treated patients undergoing autologous BMT showed significant variability in CFU-GM sensitivity to 4HC. The combined effects of incubation RBC concentration and individual patient 4HC sensitivity appear to account for most of the variability in CFU-GM recovery and speed of hematologic recovery after clinical purging with 4HC.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3311205

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  3 in total

Review 1.  Bone marrow purging with mafosfamide--a critical survey.

Authors:  H Sindermann; M Peukert; P Hilgard
Journal:  Blut       Date:  1989-11

2.  A pilot pharmacologic biomarker study in HLA-haploidentical hematopoietic cell transplant recipients.

Authors:  Meagan J Bemer; Mohamed Sorror; Brenda M Sandmaier; Paul V O'Donnell; Jeannine S McCune
Journal:  Cancer Chemother Pharmacol       Date:  2013-08-02       Impact factor: 3.333

3.  Reduction in levels of the cyclin-dependent kinase inhibitor p27(kip-1) coupled with transforming growth factor beta neutralization induces cell-cycle entry and increases retroviral transduction of primitive human hematopoietic cells.

Authors:  M A Dao; N Taylor; J A Nolta
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-27       Impact factor: 11.205

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.